Prognostic and predictive relevance of primary tumor location in patients with ras wild-type metastatic colorectal cancer retrospective analyses of the CRYSTAL and FIRE-3 trials

JAMA Oncology

Volumn 3, Issue 2, 2017, Pages 194-201

  Tejpar, Sabine ^a   Stintzing, Sebastian ^b   Ciardiello, Fortunato ^c   Tabernero, Josep ^d   Van Cutsem, Eric ^a   Beier, Frank ^e   Esser, Regina ^e   Lenz, Heinz Josef ^f   Heinemann, Volker ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF MUNICH   (Germany)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e MERCK KGAA   (Germany)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018205885     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3797     Document Type: Conference Paper

References (25)

1. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment formetastatic colorectal cancer. N Engl J Med. 2009;360(14):1408-1417.
2. Van Cutsem E, Köhne CH, Láng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment formetastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29(15):2011-2019.
3. Van Cutsem E, Lenz HJ, Köhne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol. 2015;33(7):692-700.
4. Heinemann V, vonWeikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075.
5. Missiaglia E, Jacobs B, D'Ario G, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014; 25(10):1995-2001.
6. LaPointe LC, Dunne R, Brown GS, et al. Map of differential transcript expression in the normal human large intestine. Physiol Genomics. 2008;33 (1):50-64.
7. Dienstmann R, Guinney J, Delorenzi M, et al. Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. ASCO Meeting Abstracts 2014: abstr 3511.
8. Guinney J, Dienstmann R,Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350-1356.
9. Modest DP, Schulz C, vonWeikersthal LF, et al. Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment). Anticancer Drugs. 2014;25(2):212-218.
10. von Einem JC, Heinemann V, vonWeikersthal LF, et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol. 2014;140(9):1607-1614.
11. Price TJ, Buizen L, Hardingham J, et al. Molecular subgroups from the AGITG MAX trial; right or left primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC). Ann Oncol. 2014;25(suppl 4):iv167-iv209.
12. Boisen MK, Johansen JS, Dehlendorff C, et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. Ann Oncol. 2013;24(10):2554-2559.
13. Loupakis F, Yang D, ZhangWet al. Primary side of origin affects the outcome of mCRC patients treated with first-line FOLFIRI plus bevacizumab independently of BRAF status and mucinous histology. J Clin Oncol 30. 2012;suppl: abstr 3549.
14. Sinicrope FA, MahoneyMR, Yoon HH, et al; Alliance for Clinical Trials in Oncology. Analysis of molecular markers by anatomic tumor site in stage III colon carcinomas from adjuvant chemotherapy trial NCCTG N0147 (Alliance). Clin Cancer Res. 2015; 21(23):5294-5304.
15. Seligmann JF. Primary Tumour Location (PTL) as a prognostic and predictive factor in advanced colorectal cancer: data from 2075 patients in randomised trials. Ann Oncol. 2014;25(suppl 4):iv172.
16. Loupakis F, Yang D, Yau L, et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst. 2015;107(3): dju427.
17. Zhang Y,Ma J, Zhang S, et al. A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. Int J Colorectal Dis. 2015; 30(9):1173-1183.
18. Sunakawa Y, IchikawaW, Tsuji A, et al. Prognostic impact of primary tumor location on survival time in patients (pts) with metastatic colorectal cancer (mCRC) treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06. J Clin Oncol 34. 2016;suppl 4S:abstr 613.
19. Brulé SY, Jonker DJ, Karapetis CS, et al. Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. Eur J Cancer. 2015;51(11): 1405-1414.
20. Wang F, Bai L, Liu TS, et al. Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab. Chin J Cancer. 2015;34(9): 384-393.
21. Powell AE,Wang Y, Li Y, et al. The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell. 2012;149(1):146-158.
22. Le DT, Uram JN,Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
23. Venook, AP. Impact of primary (1) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance). J Clin Oncol 34. 2016;suppl 4S:abstr 3504.
24. Lenz HJ, Lee FC, Yau L, et al. MAVERICC, a phase 2 study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV with biomarker stratification as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 34. 2016;suppl 4S:abstr 493.
25. HeWZ, Yang Q, Jiang C et al. Bevacizumab effectiveness and primary tumor location in metastatic colorectal cancer patients. J Clin Oncol 34. 2016;suppl 4S:abstr 683.